The Versatility of Multiplex Antibody Titer Assays for COVID-19 and Beyond

July 8th, 2020 / Stephen Angeloni

  The COVID-19 outbreak that began in Wuhan, China in December 2019 was marked by an increase in the number of cases showing pneumonia-like symptoms.1,2 It was not until about a month after the outbreak began that genomic analysis identified a novel coronavirus as the causative agent. With the emergence of new pathogen strains, genomic

Continue reading »

xMAP® Connect Virtual Conference – Inspiring Multiplexing Innovation

June 24th, 2020 / Hilary Graham

Luminex is proud to announce the xMAP® Connect Virtual Conference, hosted online this year by LabRoots. The goal of this conference is to connect fellow xMAP enthusiasts and provide best practices for multiplex assays, virtually from anywhere in the world. Luminex’s xMAP® Technology enables the evaluation of up to 500 analytes simultaneously in a single

Continue reading »

The Faces of Luminex: Eva Oleksy, Clinical Research

June 19th, 2020 / Christina Olivas

Luminex develops a number of instruments and molecular diagnostic tests that have to be reviewed by regulatory agencies before becoming commercially available. Each of them requires clinical trials to demonstrate accuracy and utility. For this, we count on team members like Eva Oleksy, Senior Clinical Research Associate. She joined Luminex in 2009, and holds a

Continue reading »

In Germany, Screening for COVID-19 with the ARIES® System

June 16th, 2020 / Sherry Dunbar, PhD

Clinical lab scientist describes his experience establishing a two-step diagnostic algorithm for COVID-19 Scientists in clinical labs worldwide have worked night and day in the COVID-19 pandemic to develop, validate, and implement new diagnostic tests for patients believed to be infected by the SARS-CoV-2 virus. While each lab’s experiences are slightly different, there are certain

Continue reading »

Luminex’s Flexible SARS-CoV-2 Assays Enable Both High-Throughput and Emergency Testing

June 11th, 2020 / Sherry Dunbar, PhD

Federal funding and FDA Emergency Use Authorization streamlined development and commercialization of these new assays. As the COVID-19 pandemic swept across the globe, people everywhere have raced to respond. The Luminex team has been working around the clock on much-needed molecular diagnostic assays for the SARS-CoV-2 virus, two of which recently received Emergency Use Authorization

Continue reading »

Questions to Ask When Choosing a Multiplex Assay Kit

June 5th, 2020 / Carrie Wittmer

  With the COVID-19 pandemic in full swing, many researchers are looking to multiplex assays to evaluate what they call the “cytokine storm.” This refers to the increase in pro-inflammatory cytokines like IL-6 in patients with COVID-19, which is believed to predict disease severity.1 Many of Luminex’s Partners already have multiplex assays available for research

Continue reading »

How Luminex Is Supporting Research Partners’ Pandemic Response

June 2nd, 2020 / Hilary Graham

Licensed Technologies Group is finding new ways to boost partner programs Here at Luminex, we are working on all fronts to help fight the coronavirus pandemic. The most visible activities have been the launch of new diagnostic tests—namely, the NxTAG® CoV Extended Panel and the ARIES® SARS-CoV-2 Assay—both of which received Emergency Use Authorization from

Continue reading »

Considerations Regarding RNA Extraction Kits for SARS-CoV-2 Detection

May 21st, 2020 / Jackie Surls

The novel coronavirus disease (COVID-19) pandemic continues to trigger rapid development of molecular diagnostic tests around the world. Nucleic acid amplification-based tests (NAATs)—such as real-time PCR and isothermal amplification—are the gold standard in molecular diagnostic technologies that are being utilized to detect SARS-CoV-2, the COVID-19 disease-causing virus.1 There are two critical and sequential steps that

Continue reading »

Webinar: Mouse Model Analysis Is Better with Multiplexing

May 13th, 2020 / Hilary Graham

Query hundreds of immunoassay targets, even with limited sample volume To make the most of immunology-focused assays using the limited tissue and fluid samples available from mouse models, scientists should consider using xMAP® Technology from Luminex, according to Daniel Braunschweig, Proteomics Field Application Scientist Leader at Bio-Rad Laboratories. That’s the takeaway from a 30-minute webinar

Continue reading »

How to Choose an Assay Development Platform

April 24th, 2020 / Chris Haake

The Luminex Team knows assay development. Check out some tips from our experts below. If you need to design a new assay, there are several factors you’ll want to consider before selecting the platform you’ll develop it on. Based on our experience, these are the most important: Analyte of interest: Is your assay meant to

Continue reading »